Immuno-therapy

Target

Pt No.

Stage

Results

BEC2/BCG

GD3

III

Limited stage SCLC

OS 16.4 months with BSC and 14.3 months with BEC2/BCG; HR = 1.12; 95% CI: 0.91-1.371 [55]

Ipilimumab or placebo + paclitaxel/carboplatin

CTLA-4

II

Previously untreated extensive stage SCLC

Phased Ipilimumab improved irPFS vs. control (HR: 0.64; P = 0.03) [56]

Ipilimumab/carboplatin/etoposide

CTLA-4

II

Previously untreated extensive stage SCLC

Ongoing [57]

Carboplatin/etoposide +/– ipilimumab

CTLA-4

III

Previously untreated extensive stage SCLC

Ongoing [58]

Nivolumab +/– ipilimumab

PD1 and CTLA-4

II

Previously treated after first line extensive stage SCLC

Ongoing [59]